- 20% off
- 20% off
Tadalafil belongs to a family of medicines called phosphodiesterase five inhibitors (PDE5). These prevent an enzyme from working too quickly. The penis is one of the areas where this enzyme works.
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, the inhibition of PDE5 by tadalafil produces increased cGMP levels in the corpus cavernosum.
For the condition of BPH, the prostate gland is enlarged but isn’t cancerous. It can pinch or squeeze your urethra (the tube that carries urine from the kidneys out of the body). Symptoms of BPH include trouble urinating, painful urination, and a frequent or urgent need to urinate.
With ED, the penis doesn’t fill up with enough blood to harden and expand when a man is sexually excited. ED can also prevent a man from keeping an erection.
In both of these conditions, increased blood flow is beneficial.
Tadalafil was discovered by Glaxo Wellcome (now GlaxoSmithKline) under a partnership between Glaxo and ICOS to develop new drugs that began in August 1991.
Cialis and Viagra are both PDE5 inhibitors used for the treatment of erectile dysfunction (ED). Both only work when a man is sexually aroused. Cialis lasts for around 36 hours compared with only 4 to 5 hours for Viagra. Food does not affect the activity of Cialis, whereas food may decrease the effectiveness of Viagra. Cialis can be used daily, at a smaller dosage, and effectively treating benign prostatic hyperplasia (BPH). Dosage of Cialis may need to be reduced in men with liver or kidney problems, and the risk of interactions may be higher than with Viagra.
Tadalafil relaxes muscles, which allows an increase in blood flow to the penis.
Tadalafil treats symptoms of an enlarged prostate (benign prostatic hyperplasia (BPH) that usually present with weak urine flow, frequency, and urgency problems.
Tadalafil can treat pulmonary arterial hypertension symptoms (PAH), improve blood volume to the lungs during exercise, and reduce the workload on the heart.
Tadalafil is not for everyone. Studies have shown that in clinical trials conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Tadalafil was administered to over 9000 men during clinical trials worldwide. In trials of CIALIS for once daily use, a total of 1434, 905, and 115 were treated for at least six months, one year, and two years, respectively. For CIALIS for use as needed, over 1300 and 1000 subjects were treated for at least six months and one year, respectively.
This data has been analyzed to look at results and side effects in humans.
IUPAC Name - (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
CAS Number - 171596-29-5
Formula - C22H19N3O4
Molar Mass - 392.4 g/mol